Dr. Agarwal's Health Care Limited (NSE: AGARWALEYE, BSE: 544350) is a Chennai, Tamil Nadu-based company in the Hospitals and Healthcare Centers industry. With a market capitalisation of ₹17,568 Cr, it ranks #403 by market cap among the 6,197 Indian listed companies on FinBizNet, and #9 of 46 in Hospitals and Healthcare Centers. At ₹549.50 (as of 16 Nov 2026), the share price is 3.9% below its 52-week high of ₹571.90 and 37.0% above its 52-week low of ₹401.00. The share price is up 9.3% over one year and up 8.3% over three months.
| Current Price | ₹549.50 |
|---|---|
| Market Cap | ₹17,568 Cr |
| NSE Symbol | AGARWALEYE |
| BSE Code | 544350 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Facilities > Hospitals and Healthcare Centers |
| P/E Ratio | 131.9 |
| Return on Equity | 8.31% |
| Return on Assets | 4.81% |
| 52-Week Range | ₹401.00 – ₹571.90 |
| 1-Year Price Change | +9.3% |
| 3-Month Price Change | +8.3% |
| Beta (1Y) | 0.23 |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.dragarwals.co.in |
| Revenue | ₹655 Cr |
|---|---|
| Net Profit | ₹57 Cr |
| Net Margin | 8.7% |
| EPS (Basic) | ₹1.65 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Dr. Agarwal's Health Care Limited reported revenue of ₹655 Cr in Q2 FY27, up 31.4% from ₹499 Cr in Q2 FY26 and up 6.7% from ₹614 Cr in Q1 FY27. It posted a net profit of ₹57 Cr for the quarter, against a net profit of ₹36 Cr in Q2 FY26 (up 55.8%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹460 Cr (Q4 FY25) to ₹655 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹655 Cr | ₹57 Cr | 8.7% |
| Q1 FY27 | ₹614 Cr | ₹55 Cr | 9.0% |
| Q4 FY26 | ₹564 Cr | ₹50 Cr | 8.9% |
| Q3 FY26 | ₹530 Cr | ₹44 Cr | 8.2% |
| Q2 FY26 | ₹499 Cr | ₹36 Cr | 7.3% |
| Q1 FY26 | ₹487 Cr | ₹38 Cr | 7.8% |
| Q4 FY25 | ₹460 Cr | ₹43 Cr | 9.2% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 32.33% of Dr. Agarwal's Health Care Limited's shares as of Sept 2026, against 32.42% in Sept 2025 (−0.09 percentage points). Delivery averaged 52.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Dr. Agarwal's Health Care Limited engages in running, owning, and managing eye care hospitals, opticals, pharmacies, etc. and related services in India and internationally. It offers femto cataracts, lenticular procedure, retinal surgeries, anterior segment reconstruction, and corneal transplants, as well as refractive and other surgeries. The company also develops, designs, manufactures, imports, and exports healthcare devices, which include ophthalmic diagnostic devices, such as auto perimeter, optical biometers, and ophthalmoscopes. In addition, the company offers consultations, diagnoses, and non-surgical treatments; and sells opticals, contact lenses and accessories, and eye care related pharmaceutical products. Dr. Agarwal's Health Care Limited was incorporated in 2010 and is based in Chennai, India.
1. Eye Care Related Sales and Services-This segment provides a range of eye care services, including cataract, refractive, and other surgeries; and consultation, diagnosis, and non-surgical treatment services. It also sells optical, contact lenses and accessories, and eye care related pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Eye Care Related Sales and Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹1,23,712 Cr | 63 | 21.50% | ₹7,615 Cr | +11.6% |
| Max Healthcare Institute Ltd | ₹91,978 Cr | 63.9 | 14.33% | ₹2,569 Cr | -16.6% |
| Manipal Health Enterprises Ltd | ₹89,110 Cr | 88.4 | — | ₹3,399 Cr | — |
| Aster Dm Healthcare Limited (Asterdm) | ₹63,041 Cr | 97.6 | 10.07% | ₹2,829 Cr | +4.3% |
| Fortis Healthcare Ltd. | ₹58,283 Cr | 55.1 | 11.01% | ₹2,735 Cr | -25.1% |
| Global Health Ltd (Medanta) | ₹38,422 Cr | 69.7 | 15.03% | ₹1,469 Cr | +16.2% |
| Narayana Hrudayalaya Limited | ₹37,907 Cr | 46.2 | 19.85% | ₹2,844 Cr | +2.8% |
| Krishna Institute Of Medical Science (KIMS) | ₹29,056 Cr | 120.6 | 9.72% | ₹1,344 Cr | +0.2% |
| Dr. Agarwal's Health Care Limited | ₹17,568 Cr | 131.9 | 8.31% | ₹655 Cr | +9.3% |
Listed by market capitalisation. Ratios are shown for context only.
Dr. Agarwal's Health Care Limited is trading at ₹549.50, with a market capitalisation of ₹17,568 Cr.
Dr. Agarwal's Health Care Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).
Dr. Agarwal's Health Care Limited has a P/E of 131.9 and a return on equity of 8.31%.
Dr. Agarwal's Health Care Limited is listed on the NSE under the symbol AGARWALEYE and on the BSE under the scrip code 544350.
Dr. Agarwal's Health Care Limited's share price is up 9.3% over one year and up 8.3% over three months. Its 52-week range is ₹401.00 to ₹571.90.
In Q2 FY27, Dr. Agarwal's Health Care Limited reported revenue of ₹655 Cr and net profit of ₹57 Cr, with basic EPS of ₹1.65 (consolidated, parsed from the company's exchange filing).
Dr. Agarwal's Health Care Limited reported revenue of ₹655 Cr in Q2 FY27, up 31.4% from ₹499 Cr in Q2 FY26 and up 6.7% from ₹614 Cr in Q1 FY27.
Promoters held 32.33% of Dr. Agarwal's Health Care Limited's shares as of Sept 2026, against 32.42% in Sept 2025 (−0.09 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.